WO2003101375A3 - Immunostimulatory oligonucleotides and uses thereof - Google Patents

Immunostimulatory oligonucleotides and uses thereof Download PDF

Info

Publication number
WO2003101375A3
WO2003101375A3 PCT/EP2003/005691 EP0305691W WO03101375A3 WO 2003101375 A3 WO2003101375 A3 WO 2003101375A3 EP 0305691 W EP0305691 W EP 0305691W WO 03101375 A3 WO03101375 A3 WO 03101375A3
Authority
WO
WIPO (PCT)
Prior art keywords
stimulation
immune response
cytokine production
immunostimulatory oligonucleotides
differentiation
Prior art date
Application number
PCT/EP2003/005691
Other languages
French (fr)
Other versions
WO2003101375A2 (en
Inventor
Ricardo Augustin Lopez
Original Assignee
Immunotech Sa
Ricardo Augustin Lopez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotech Sa, Ricardo Augustin Lopez filed Critical Immunotech Sa
Priority to AT03755959T priority Critical patent/ATE541039T1/en
Priority to ES03755959T priority patent/ES2380796T3/en
Priority to CA002487904A priority patent/CA2487904A1/en
Priority to JP2004508733A priority patent/JP4568907B2/en
Priority to EP03755959A priority patent/EP1511845B1/en
Priority to NZ536962A priority patent/NZ536962A/en
Priority to AU2003250334A priority patent/AU2003250334B2/en
Priority to DK03755959.8T priority patent/DK1511845T3/en
Priority to KR10-2004-7019524A priority patent/KR20050005521A/en
Priority to MXPA04011937A priority patent/MXPA04011937A/en
Publication of WO2003101375A2 publication Critical patent/WO2003101375A2/en
Publication of WO2003101375A3 publication Critical patent/WO2003101375A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

Oligonucleotides containing the non-palindromic sequence motif X1X2X3X4X5X6X7X8, wherein X1 is C or T, X2 is C, T, G or A, X3 is T or A, X4 is T, C or G, X5 is T, C or G, X6 is T or G, X7 is G and X8 is T and wherein at least two of X3, X4, X5 and X6 are Ts and wherein C never precedes G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotides) that have the ability to stimulate the immune response of animals of the order Primate, including humans are disclosed. The stimulation of the immune response is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production in B-cells and cell differentiation and cytokine production in plasmacytoid dendritic cells.
PCT/EP2003/005691 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof WO2003101375A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT03755959T ATE541039T1 (en) 2002-05-30 2003-05-30 IMMUNO-STIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
ES03755959T ES2380796T3 (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and their uses.
CA002487904A CA2487904A1 (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof
JP2004508733A JP4568907B2 (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof
EP03755959A EP1511845B1 (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof
NZ536962A NZ536962A (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof
AU2003250334A AU2003250334B2 (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof
DK03755959.8T DK1511845T3 (en) 2002-05-30 2003-05-30 IMMUNSTIMULATORY OLIGONUCLEOTIDES AND APPLICATIONS THEREOF
KR10-2004-7019524A KR20050005521A (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof
MXPA04011937A MXPA04011937A (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002388049A CA2388049A1 (en) 2002-05-30 2002-05-30 Immunostimulatory oligonucleotides and uses thereof
CA2,388,049 2002-05-30

Publications (2)

Publication Number Publication Date
WO2003101375A2 WO2003101375A2 (en) 2003-12-11
WO2003101375A3 true WO2003101375A3 (en) 2004-09-02

Family

ID=29589083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005691 WO2003101375A2 (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof

Country Status (14)

Country Link
US (4) US7038029B2 (en)
EP (1) EP1511845B1 (en)
JP (1) JP4568907B2 (en)
KR (1) KR20050005521A (en)
AT (1) ATE541039T1 (en)
AU (1) AU2003250334B2 (en)
CA (1) CA2388049A1 (en)
CY (1) CY1112588T1 (en)
DK (1) DK1511845T3 (en)
ES (1) ES2380796T3 (en)
MX (1) MXPA04011937A (en)
NZ (1) NZ536962A (en)
PT (1) PT1511845E (en)
WO (1) WO2003101375A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399658B2 (en) 2011-03-28 2016-07-26 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0879284B1 (en) * 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1985702A3 (en) * 2000-12-08 2010-08-18 Coley Pharmaceutical GmbH CPG-like nucleic acids and methods of use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
FR2848565B1 (en) * 2002-12-16 2007-04-06 Ets Francais Du Sang LINE OF GEN2.2 DENDRITIC CELLS
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP1642585A1 (en) * 2004-09-27 2006-04-05 Immunotech S.A. Osteogenic oligonucleotides and uses thereof
EP1657307A1 (en) * 2004-11-16 2006-05-17 Immunotech S.A. Oligonucleotides that induce the secretion of GM-CSF
KR100740237B1 (en) * 2005-05-10 2007-07-18 아이진 주식회사 Adjuvant comprising oligonucleotide and non-toxic LPS
EP1728514A1 (en) * 2005-06-03 2006-12-06 Immunotech S.A. Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
WO2007089051A1 (en) * 2006-02-01 2007-08-09 Eyegene Inc. Composition for treating cancer comprising oligonucleotide and non-toxic lps
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn Structure and use of 5' phosphate oligonucleotides
MX2009003398A (en) 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
EP2338499A1 (en) 2006-10-10 2011-06-29 Gunther Hartmann 5' triphosphate oligonucleotide induces anti-viral response
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
WO2008131074A1 (en) * 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
NZ727616A (en) 2008-06-27 2018-06-29 Zoetis Services Llc Novel adjuvant compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CA3033133C (en) 2009-03-25 2021-11-09 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
EP2757988A4 (en) 2009-06-15 2015-08-19 Jackson Roger P Polyaxial bone anchor with pop-on shank and winged insert with friction fit compressive collet
AU2010303934B2 (en) 2009-10-05 2014-03-27 Roger P. Jackson Polyaxial bone anchor with non-pivotable retainer and pop-on shank, some with friction fit
US20120321699A1 (en) 2010-02-25 2012-12-20 Haynes Barton F Method of inducing the production of protective anti-hiv-1 antibodies
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
GB2502449A (en) 2010-11-02 2013-11-27 Roger P Jackson Polyaxial bone anchor with pop-on shank and pivotable retainer
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
FR2975600B1 (en) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris AGENTS FOR THE TREATMENT OF TUMORS
US9562066B2 (en) 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2015042423A2 (en) 2013-09-19 2015-03-26 Zoetis Llc Vaccine
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
CN106535876B (en) 2014-06-04 2020-09-11 埃克西奎雷股份有限公司 Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2017537619A (en) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes
SG11201705737RA (en) 2015-01-16 2017-08-30 Zoetis Services Llc Foot-and-mouth disease vaccine
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2019147509A1 (en) * 2018-01-26 2019-08-01 The Regents Of The University Of California Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
WO2019165447A1 (en) * 2018-02-26 2019-08-29 Claudia Zylberberg Immune cell activation
WO2022094102A1 (en) * 2020-10-30 2022-05-05 Mid-Atlantic Biotherapeutics, Inc. Immunostimulatory oligonucleotides for the prevention and treatment of covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022990A2 (en) * 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3555952B2 (en) * 1993-04-30 2004-08-18 バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング Antisense-oligonucleotides for treating the immunosuppressive effect of transforming growth factor-β (TGF-β)
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US5968909A (en) * 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE441432T1 (en) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst USE OF NON-METHYLATED CPG DINUCLEOTIDE IN COMBINATION WITH ALUMINUM AS ADJUVANTS
JP2001526688A (en) 1997-05-19 2001-12-18 メルク エンド カンパニー インコーポレーテッド Oligonucleotide adjuvant
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
CA2291483C (en) * 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
FR2773032B1 (en) 1997-12-22 2001-12-21 Nortel Matra Cellular MODULATION OF A NARROW SPECTRUM SIGNAL WITH A SUBSTANTIALLY CONSTANT ENVELOPE
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JPH11209289A (en) * 1998-01-22 1999-08-03 Taisho Pharmaceut Co Ltd Mucosal immunity inducer
ES2284247T3 (en) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS.
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
CA2341338A1 (en) 1998-09-03 2000-03-16 Coley Pharmaceutical Gmbh G-motif oligonucleotides and uses thereof
US6497360B1 (en) 2000-07-26 2002-12-24 In-Store Media Systems, Inc. Prompt coupon reimbursement after coupon redemption
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
BRPI0010612B8 (en) 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vaccines
AU762857B2 (en) 1999-04-20 2003-07-10 Smithkline Beecham Biologicals (Sa) Vaccine
EP1177439B1 (en) * 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening for immunostimulatory dna functional modifiers
CA2372960C (en) 1999-05-06 2006-03-28 The Immune Response Corporation Hiv immunogenic compositions and methods
WO2000075304A1 (en) 1999-06-08 2000-12-14 Aventis Pasteur Immunostimulant oligonucleotide
DE60023300T2 (en) 1999-06-29 2006-07-06 Glaxosmithkline Biologicals S.A. USE OF CPG AS ADJUVANS FOR HIV PULP
GB9915204D0 (en) 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE19935756A1 (en) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
EP2314693A3 (en) 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1226252A2 (en) 1999-11-02 2002-07-31 Chiron Corporation DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
EP1246848A1 (en) 1999-12-27 2002-10-09 University Of Manitoba GENETIC VACCINES FOR THE PRODUCTION OF CHICKEN EGG-YOLK ANTIBODIES AGAINST ENTEROTOXIGENIC i ESCHERICHIA COLI /i AND OTHER PATHOGENS
CA2397374A1 (en) 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
CA2398432C (en) 2000-01-26 2012-06-19 Hybridon, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
US6552006B2 (en) 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
FR2805265B1 (en) 2000-02-18 2002-04-12 Aventis Pasteur IMMUNOSTIMULATING OLIGONUCLEOTIDES
FR2805264B1 (en) 2000-02-18 2002-04-12 Aventis Pasteur IMMUNOSTIMULATING OLIGONUCLEOTIDES
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
EP1263773A4 (en) 2000-03-14 2005-08-31 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
CA2407942A1 (en) 2000-05-01 2001-11-08 Hybridon, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
KR100799788B1 (en) 2000-06-08 2008-01-31 인터셀 아게 Immunostimulatory oligodeoxynucleotides
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en) * 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
IL154557A0 (en) 2000-08-25 2003-09-17 Yeda Res & Dev Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1985702A3 (en) 2000-12-08 2010-08-18 Coley Pharmaceutical GmbH CPG-like nucleic acids and methods of use thereof
FR2819724B1 (en) 2001-01-22 2005-05-13 Inst Necker MEANS FOR INDUCING AN IMMUNE RESPONSE TO POLYCHARIDIC BACTERIAL ANTIGENS AND PROTEIN STRUCTURES OF VIRUS CAPSIDS
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
CA2447793A1 (en) 2001-05-21 2002-11-28 Intercell Ag Immunostimulatory oligodeoxynucleic molecules
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
JP4370161B2 (en) 2001-06-29 2009-11-25 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド HCVE1E2 vaccine composition
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
EP1588390B1 (en) 2003-01-31 2012-08-29 Freni Brembo S.p.A. Switch

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
WO2001022990A2 (en) * 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
90TH ANNIVERSARY ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS; DENVER, CO, USA; MAY 06-10, 2003 *
ELIAS FERNANDA ET AL: "Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs.", JOURNAL OF IMMUNOLOGY, vol. 171, no. 7, 1 October 2003 (2003-10-01), pages 3697 - 3704, XP002276022, ISSN: 0022-1767 *
HARTMANN G ET AL: "Mechanism and function of a newly identified CpG DNA motif in human primary B cells.", JOURNAL OF IMMUNOLOGY, vol. 164, no. 2, 15 January 2000 (2000-01-15), pages 944 - 953, XP002276021, ISSN: 0022-1767 *
MARIOTTI S ET AL: "Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant", VACCINE, vol. 20, no. 17-18, 22 May 2002 (2002-05-22), pages 2229 - 2239, XP004353929, ISSN: 0264-410X *
NEST VAN G ET AL: "AN IMMUNOSTIMULATORY OLIGONUCLEOTIDE (ISS ODN) ENHANCES IMMUNE RESPONSES TO HBV VACCINE IN A VARIETY OF ANIMAL SPECIES INCLUDING PRIMATES", ANNUAL ICAAC ABSTRACTS, vol. 39, 26 September 1999 (1999-09-26), pages 374, AN679, XP001070533 *
RODRIGUEZ JUAN M ET AL: "Potent (non-CpG) immunostimulatory oligonucleotides.", FASEB JOURNAL, vol. 17, no. 7, 14 April 2003 (2003-04-14), pages C289, XP008029386, ISSN: 0892-6638 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399658B2 (en) 2011-03-28 2016-07-26 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags

Also Published As

Publication number Publication date
AU2003250334A1 (en) 2003-12-19
ES2380796T3 (en) 2012-05-18
US20050276789A1 (en) 2005-12-15
US20130243811A1 (en) 2013-09-19
DK1511845T3 (en) 2012-05-07
NZ536962A (en) 2006-09-29
CA2388049A1 (en) 2003-11-30
JP4568907B2 (en) 2010-10-27
KR20050005521A (en) 2005-01-13
WO2003101375A2 (en) 2003-12-11
EP1511845B1 (en) 2012-01-11
EP1511845A2 (en) 2005-03-09
US20090060937A1 (en) 2009-03-05
AU2003250334B2 (en) 2008-06-05
US8871436B2 (en) 2014-10-28
PT1511845E (en) 2012-04-13
JP2005533491A (en) 2005-11-10
CY1112588T1 (en) 2016-02-10
US20040006032A1 (en) 2004-01-08
US7038029B2 (en) 2006-05-02
ATE541039T1 (en) 2012-01-15
MXPA04011937A (en) 2006-06-27
US7943316B2 (en) 2011-05-17
US7381807B2 (en) 2008-06-03

Similar Documents

Publication Publication Date Title
WO2003101375A3 (en) Immunostimulatory oligonucleotides and uses thereof
EP0691980A1 (en) 7-deazapurine modified oligonucleotides
HK1067547A1 (en) Combination motif immune stimulatory oligonucleotides with improved activity
EP2039762A3 (en) Nitralases
EP1857547A3 (en) Further novel forms of interfering RNA molecules
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
CA2325351A1 (en) Non-stochastic generation of genetic vaccines and enzymes
CA2418961A1 (en) Anti-il-12 antibodies, compositions, methods and uses
EP2397549A3 (en) Non-stochastic generation of genetic vaccines and enzymes
AU2002339458A1 (en) Sirna knockout assay method and constructs
ZA9811501B (en) Method to enhance an immune response of nucleic acid vaccination.
WO2003006625A8 (en) Nucleotide compositions comprising photocleavable markers and methods of preparation thereof
EP1390472A4 (en) Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2004042029A3 (en) Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
CA2283509A1 (en) Novel bicyclonucleoside and oligonucleotide analogue
WO1999055857A3 (en) Nucleoside triphosphates and their incorporation into ribozymes
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
EP1808180A3 (en) Modified GP 100 and uses thereof
WO2001044465A3 (en) Therapeutically useful synthetic oligonucleotides
WO2000053776A3 (en) Human kallikrein-like genes
IL161901A0 (en) Nucleosides, preparation thereof and use as inhibiDevice for the reading and the signalling of environmental parameters tors of rna viral polymerases
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2003031459A3 (en) Modulation of the expression of genes dependent on stat-1
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2004-502009

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004508733

Country of ref document: JP

Ref document number: 2003250334

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020047019524

Country of ref document: KR

Ref document number: 2487904

Country of ref document: CA

Ref document number: 3773/DELNP/2004

Country of ref document: IN

Ref document number: PA/A/2004/011937

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 536962

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003755959

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047019524

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003755959

Country of ref document: EP